ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
48 announcements with these filters
Dr. Agarwal's Health Care Ltd held a creditor meeting for its amalgamation with Dr. Agarwal's Eye Hospital. The meeting, convened by NCLT, considered the scheme under Companies Act provisions.
Dr. Agarwal's Health Care Ltd held an NCLT-convened shareholder meeting to approve its amalgamation with Dr. Agarwal's Eye Hospital Ltd. The meeting was convened to pass a special majority resolution under the Companies Act.
CRISIL reaffirmed and withdrew its AA- rating on Dr. Agarwal's debt facilities. The withdrawal follows a company request with lender consent; ICRA continues to rate the facilities.
Dr. Agarwal's Health Care Limited convened an NCLT-ordered shareholder meeting for July 02, 2026, to approve its amalgamation with Dr. Agarwal's Eye Hospital Limited. The merger aims to consolidate eye care operations and improve capital efficiency.
Dr. Agarwal's Health Care completed incorporating a new wholly owned subsidiary in Ethiopia. The ₹2,000,000 Crore transaction marks the firm's strategic entry into the Ethiopian market.
Dr. Agarwal’s reported strong FY26 performance, crossing INR 2,000cr revenue milestone with significant network expansion and EBITDA margin improvement to 28.9%.
Dr. Agarwal’s Health Care incorporated Orbit Health Care ETH PLC in Ethiopia via a ₹1.90 Crore investment. The new entity becomes an indirect wholly owned subsidiary.
Dr. Agarwal's Health Care Limited allotted 25,240 equity shares under its ESOP scheme. The issuance marginally increases the company's total paid-up share capital.
Dr. Agarwal's Health Care allotted 25,240 shares under its ESOP scheme, valued at ₹0.33 Crore. The allotment increases the company's total paid-up equity share capital.
Dr. Agarwals reported 21% income growth in FY26, driven by aggressive network expansion (57 new facilities) and clinical excellence.
Dr. Agarwals Health Care Ltd reported revenue from operations of ₹564.1 Cr (+22.6% YoY) and net profit of ₹50 Cr (+17.6% YoY) for Q4 FY26.
Dr. Agarwal’s Health Care reported FY2026 total income of ₹2125.00 Crore, a 20.9% year-on-year growth. Net profit surged 52.4% to ₹168 Crore alongside significant network expansion.
Dr. Agarwals Health Care received a ₹20.50 Crore GST show cause notice for FY 2023-24. The company is evaluating legal steps to respond within thirty days.
Dr. Agarwal’s Health Care scheduled a board meeting for May 21, 2026, to approve annual financial results. An earnings call will follow the meeting same day.
Dr. Agarwal’s Health Care received NCLT approval to convene shareholder and creditor meetings regarding its amalgamation with AEHL. Meetings are scheduled for July 02, 2026.
Dr. Agarwal's Health Care Limited allotted 1,50,282 equity shares under its ESOP/ESPS scheme. This increased the company's paid-up share capital from 31,68,07,506 to 31,69,57,788. Such allotments align employee interests with corporate performance and lead to a marginal expansion of the equity base.
Dr. Agarwal's Health Care Ltd allotted 1,50,282 equity shares valued at approximately ₹1.95 Crore following the exercise of employee stock options. This allotment increases the company's paid-up equity share capital to ₹31.69 Crore.
Dr. Agarwal's Health Care Limited submitted the Regulation 74(5) compliance certificate for the quarter ended March 31, 2026. Issued by KFin Technologies Limited, the certificate confirms that securities dematerialisation and rematerialisation details have been furnished to the stock exchanges. This is a routine regulatory filing with no material impact on operations.